74 related articles for article (PubMed ID: 9816245)
1. Chromosome-specific aneusomy in carcinoma of the breast.
Persons DL; Robinson RA; Hsu PH; Seelig SA; Borell TJ; Hartmann LC; Jenkins RB
Clin Cancer Res; 1996 May; 2(5):883-8. PubMed ID: 9816245
[TBL] [Abstract][Full Text] [Related]
2. Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer.
Kapranos N; Kounelis S; Karantasis H; Kouri E
Breast J; 2005; 11(6):448-53. PubMed ID: 16297090
[TBL] [Abstract][Full Text] [Related]
3. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization.
Mendelin J; Grayson M; Wallis T; Visscher DW
Lab Invest; 1999 Apr; 79(4):387-93. PubMed ID: 10211991
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1 aneusomy, identified by interphase cytogenetics, in mammographically detected ductal carcinoma in situ of the breast.
Harrison M; Magee HM; O'Loughlin J; Gorey TF; Dervan PA
J Pathol; 1995 Mar; 175(3):303-9. PubMed ID: 7745499
[TBL] [Abstract][Full Text] [Related]
5. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
[TBL] [Abstract][Full Text] [Related]
6. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer.
Takehisa M; Sasa M; Bando Y; Hirose T; Morimoto T; Nagao T; Tangoku A
Anticancer Res; 2007; 27(2):1073-8. PubMed ID: 17465246
[TBL] [Abstract][Full Text] [Related]
8. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
9. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.
Dellas A; Torhorst J; Schultheiss E; Mihatsch MJ; Moch H
Clin Cancer Res; 2002 May; 8(5):1210-6. PubMed ID: 12006540
[TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
14. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
15. Chromosome alterations associated with positive and negative lymph node involvement in breast cancer.
Wuicik L; Cavalli LR; Cornélio DA; Schmid Braz AT; Barbosa ML; Lima RS; Urban CA; Bleggi Torres LF; Ribeiro EM; Cavalli IJ
Cancer Genet Cytogenet; 2007 Mar; 173(2):114-21. PubMed ID: 17321326
[TBL] [Abstract][Full Text] [Related]
16. Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease.
Garcia J; Duran A; Tabernero MD; Garcia Plaza A; Flores Corral T; Najera ML; Gomez-Alonso A; Orfao A
Cytometry B Clin Cytom; 2003 Jan; 51(1):14-20. PubMed ID: 12500293
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
18. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 1 aneusomy with 1p36 under-representation is related to histologic grade, DNA aneuploidy, high c-erb B-2 and loss of bcl-2 expression in ductal breast carcinoma.
Farabegoli F; Ceccarelli C; Santini D; Trerè D; Baldini N; Taffurelli M; Derenzini M
Int J Cancer; 1996 Oct; 69(5):381-5. PubMed ID: 8900371
[TBL] [Abstract][Full Text] [Related]
20. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
